Testing iStep-MS, a new programme to encourage physical activity
The study in brief
Getting started and then continuing with regular physical activity can be a struggle. Researchers have developed a programme (iStep-MS) which encourages people with MS to be more active. Before testing it in a large-scale clinical study, the researchers wanted to be sure that the course was safe and acceptable for participants and suitable for physiotherapists to provide.
Participants who were able to walk at home with or without a walking aid were recruited to the study which was carried out at the Berkshire MS Therapy Centre. 30 people were assigned to take part in the programme and 30 had routine support.
Participants taking part in iStep-MS received four face-to-face sessions with a physiotherapist at the centre over 3 months, backed up by a printed handbook. The physiotherapist discussed benefits of increased exercise and encouraged and supported the participant to spend less time sitting down and increase time spent in physical activity. Participants set and recorded their own goals for physical activity, sedentary behaviour, and step-counts, and monitored and recorded these using diaries incorporated in the handbook.
Fatigue and pain did not increase in the iStep-MS group, indicating that encouraging people to be more active did not make symptoms worse. The number of people in the study was not enough to give an accurate indication of the effectiveness of this approach, but several measures, such as levels of pain and fatigue, were reduced in the programme group at 3 and 9 month assessments. Improvements at the 9 month assessment suggest that the course encourages long-term changes to levels of physical activity, lasting beyond the face-to-face sessions.
The researchers concluded that the course was safe, well-attended and well-received by both participants and physiotherapists. Feedback on materials and recording of physical activity will allow them to fine tune the course materials before testing the effectiveness of iStep-MS in a larger study.
The study in more detail
Background
In the past, people with MS were advised to avoid exertion but now regular, moderate exercise is recognised to be an important part of maintaining good health and wellbeing. There is evidence that it can help with many MS symptoms, and also with general quality of life. But getting started and sticking with regular physical activity can be a struggle. Researchers have developed a programme (iStep-MS) which encourages people with MS to be more active. Before testing it in a large-scale clinical study, the researchers wanted to be sure that the course was safe and acceptable for participants and suitable for physiotherapists to provide.
How this study was carried out
Participants who were able to walk in the home with or without a walking aid were recruited for the study which was carried out at the Berkshire MS Therapy Centre in the UK. 30 people were randomly assigned to take part in the programme and 30 received routine support (treatment was given as needed, this could range from intensive physiotherapy to no treatment). All participants were given a pedometer.
Participants taking part in the programme received four face-to-face sessions each lasting 30-45 minutes with a physiotherapist at the centre over 3 months, backed up by a printed handbook. The physiotherapist discussed benefits of increased exercise and encouraged and supported the participant to reduce time spent sitting down and increase time spent in physical activity. Participants set and recorded their own goals for physical activity, sedentary behaviour, and step-counts, and monitored and recorded these using diaries incorporated in the handbook.
Assessments were carried out at the beginning, and at 3 and 9 months.
What was found?
Fatigue and pain levels did not increase in the iStep-MS group. Physiotherapists reported that the programme was feasible to deliver and they were able to cover the content of each session. All bar one of the participants attended at least 3 out of the 4 sessions. Participants found the programme acceptable but suggested improvements to usability of the handbook and alternative formats for recording activity.
The number of people in the study was not enough to give an accurate indication of the effectiveness of this approach to encourage physical activity, but several measures, such as levels of pain and fatigue, improved in the programme group at 3 and 9 month assessments.
One limitation of the study was the fact that all the participants were already regular attendees of a therapy centre and may not be representative of the wider population of people with MS in the UK.
What does it mean?
Fatigue and pain did not increase in the iStep-MS group, indicating that encouraging people to improve their levels of physical activity did not lead to more severe symptoms. Improvements at the 9 month assessment point suggest that the course does lead to long-term changes to levels of physical activity, which last beyond the end of the face-to-face sessions.
The researchers concluded that the course was safe, well-attended and well-received by both participants and physiotherapists. Feedback on materials and recording of physical activity will allow them to fine tune the course materials before testing the effectiveness of iStep-MS in a larger study.
Ryan JM, Fortune J, Stennett A, et al.
Safety, feasibility, acceptability and effects of a behaviour-change intervention to change physical activity behaviour among people with multiple sclerosis: Results from the iStep-MS randomised controlled trial.
Multiple Sclerosis 2019 Oct 31 [Epub ahead of print]
Summary
Find out more about staying active with MS
If you are looking for ways to be more physically active, have a look at our web pages on exercise.
You’ll find information on how exercise can benefit MS, suggestions on how to get started and keep going with exercising, different types of exercise to suit your own circumstances as well as a selection of exercise routines, including a neuro-Pilates circuit, our stick-man exercises which you can use to build your own routine and Move it for MS, our exercise videos presented by Mr Motivator which are also available free of charge on DVD (UK only).
Browse more from the latest research
Causes of MS
Azimi A, Hanaei S, Sahraian MA, Mohammadifar M, Ramagopalan SV, Ghajarzadeh M.
Age at menarche and risk of multiple sclerosis (MS): a systematic review and meta-analysis.
BMC Neurol. 2019 Nov 14;19(1):286. doi: 10.1186/s12883-019-1473-5.
Summary(link is external)
Read the full text of this paper (link is external)
CCSVI
Zamboni P, Galeotti R, Salvi F, Giaquinta A, Setacci C, Alborino S, Guzzardi G, Sclafani SJ, Maietti E, Veroux P; Brave Dreams Research Group..
Effects of venous angioplasty on cerebral lesions in multiple sclerosis: expanded analysis of the brave dreams double-blind, sham-controlled randomized trial.
J Endovasc Ther. 2019 Nov 17:1526602819890110. doi: 10.1177/1526602819890110. [Epub ahead of print] Erratum in: J Endovasc Ther. 2020 Jan 2;:1526602819898319.
Summary(link is external)
Read the full text of this paper (link is external)
Childhood MS
Erdal JL, Kopp TI, Blinkenberg M, Petersen T, Sørensen PS, Magyari M.
Clinical characteristics and use of disease modifying therapy in the nationwide Danish cohort of paediatric onset multiple sclerosis.
Mult Scler Relat Disord. 2019 Oct 8;37:101431. doi: 10.1016/j.msard.2019.101431. [Epub ahead of print]
Summary(link is external)
Co-existing conditions
Mahamud Z, Burman J, Zelano J.
Prognostic impact of epilepsy in multiple sclerosis.
Mult Scler Relat Disord. 2019 Nov 5;38:101497. doi: 10.1016/j.msard.2019.101497. [Epub ahead of print]
Summary(link is external)
Disease modifying drugs
Sacco R, Disanto G, Maraffi I, Candrian U, Kamm CP, Rossi S, Schwegler G, Gallo A, Gobbi C, Zecca C.
Infusion-related reactions during natalizumab treatment: Do we still need a post-infusion observation period?
Mult Scler Relat Disord. 2019 Nov 12;38:101523. doi: 10.1016/j.msard.2019.101523. [Epub ahead of print]
Summary(link is external)
Sepúlveda M, Montejo C, Llufriu S, Sola-Valls N, Reyes D, Martinez-Lapiscina EH, Zubizarreta I, Pulido-Valdeolivas I, Martinez-Hernandez E, Ariño H, Baños N, Saiz A, Blanco Y.
Rebound of multiple sclerosis activity after fingolimod withdrawal due to planning pregnancy: Analysis of predisposing factors.
Mult Scler Relat Disord. 2019 Oct 30;38:101483. doi: 10.1016/j.msard.2019.101483. [Epub ahead of print]
Summary(link is external)
Barry B, Erwin AA, Stevens J, Tornatore C.
Fingolimod rebound: A review of the clinical experience and management considerations.
Neurol Ther. 2019 Dec;8(2):241-250. doi: 10.1007/s40120-019-00160-9. Epub 2019 Nov 1. Review.
Summary(link is external)
Read the full text of this paper (link is external)
Van Wijmeersch B, Singer BA, Boster A, Broadley S, Fernández Ó, Freedman MS, Izquierdo G, Lycke J, Pozzilli C, Sharrack B, Steingo B, Wiendl H, Wray S, Ziemssen T, Chung L, Margolin DH, Thangavelu K, Vermersch P.
Efficacy of alemtuzumab over 6 years in relapsing-remitting multiple sclerosis patients who relapsed between courses 1 and 2: Post hoc analysis of the CARE-MS studies.
Mult Scler. 2019 Nov 1:1352458519881759. doi: 10.1177/1352458519881759. [Epub ahead of print]
Summary(link is external)
Read the full text of this paper (link is external)
Col N, Alvarez E, Springmann V, Ionete C, Berrios Morales I, Solomon A, Kutz C, Griffin C, Tierman B, Livingston T, Patel M, van Leeuwen D, Ngo L, Pbert L.
A novel tool to improve shared decision making and adherence in multiple sclerosis: development and preliminary testing.
MDM Policy Pract. 2019 Oct 16;4(2):2381468319879134. doi: 10.1177/2381468319879134. eCollection 2019 Jul-Dec.
Summary(link is external)
Read the full text of this paper (link is external)
Okai AF, Amezcua L, Berkovich RR, Chinea AR, Edwards KR, Steingo B, Walker A, Jacobs AK, Daizadeh N, Williams MJ; CARE-MS I, CARE-MS II, CAMMS03409, and TOPAZ Investigators..
Efficacy and safety of alemtuzumab in patients of African descent with relapsing-remitting Multiple Sclerosis: 8-year follow-up of CARE-MS I and II (TOPAZ Study).
Neurol Ther. 2019 Dec;8(2):367-381. doi: 10.1007/s40120-019-00159-2. Epub 2019 Oct 25.
Summary(link is external)
Read the full text of this paper (link is external)
Lünemann JD, Ruck T, Muraro PA, Bar'Or A, Wiendl H.
Immune reconstitution therapies: concepts for durable remission in multiple sclerosis.
Nat Rev Neurol. 2020 Jan;16(1):56-62. doi: 10.1038/s41582-019-0268-z. Epub 2019 Oct 24. Review.
Summary(link is external)
Vollmer B, Ontaneda D, Harris H, Nair K, Bermel RA, Corboy JR, Fox RJ, Vollmer T, Cohen JA, Alvarez E, Hersh CM.
Comparative discontinuation, effectiveness, and switching practices of dimethyl fumarate and fingolimod at 36-month follow-up.
J Neurol Sci. 2019 Dec 15;407:116498. doi: 10.1016/j.jns.2019.116498. Epub 2019 Oct 15.
Summary(link is external)
Read the full text of this paper (link is external)
Narapureddy B, Dubey D.
Clinical evaluation of dimethyl fumarate for the treatment of relapsing-remitting multiple sclerosis: efficacy, safety, patient experience and adherence.
Patient Prefer Adherence. 2019 Oct 1;13:1655-1666. doi: 10.2147/PPA.S187529. eCollection 2019.
Summary(link is external)
Read the full text of this paper (link is external)
Drugs in development
Juto A, Fink K, Al Nimer F, Piehl F.
Interrupting rituximab treatment in relapsing-remitting multiple sclerosis; no evidence of rebound disease activity.
Mult Scler Relat Disord. 2019 Oct 24;37:101468. doi: 10.1016/j.msard.2019.101468. [Epub ahead of print]
Summary(link is external)
Naismith RT, Wolinsky JS, Wundes A, LaGanke C, Arnold DL, Obradovic D, Freedman MS, Gudesblatt M, Ziemssen T, Kandinov B, Bidollari I, Lopez-Bresnahan M, Nangia N, Rezendes D, Yang L, Chen H, Liu S, Hanna J, Miller C, Leigh-Pemberton R.
Diroximel fumarate (DRF) in patients with relapsing-remitting multiple sclerosis: Interim safety and efficacy results from the phase 3 EVOLVE-MS-1 study.
Mult Scler. 2019 Nov 4:1352458519881761. doi: 10.1177/1352458519881761. [Epub ahead of print]
Summary(link is external)
Read the full text of this paper (link is external)
Epidemiology
Rotstein DL, Marrie RA, Maxwell C, Gandhi S, Schultz SE, Fung K, Tu K.
MS risk in immigrants in the McDonald era: A population-based study in Ontario, Canada.
Neurology. 2019 Dec 10;93(24):e2203-e2215. doi: 10.1212/WNL.0000000000008611. Epub 2019 Nov 5.
Summary(link is external)
Other treatments
van Munster CEP, Kaya L, Lam KH, Kalkers NF, Killestein J, Uitdehaag BMJ.
Responder rates to fampridine differ between clinical subgroups of MS patients and patient reported outcome influences treatment decision making.
Mult Scler Relat Disord. 2019 Nov 5;38:101489. doi: 10.1016/j.msard.2019.101489. [Epub ahead of print]
Summary(link is external)
Almuklass AM, Capobianco RA, Feeney DF, Alvarez E, Enoka RM.
Sensory nerve stimulation causes an immediate improvement in motor function of persons with multiple sclerosis: A pilot study.
Mult Scler Relat Disord. 2019 Nov 6;38:101508. doi: 10.1016/j.msard.2019.101508. [Epub ahead of print]
Summary(link is external)
Marx W, Hockey M, McGuinness AJ, Lane M, Christodoulou J, van der Mei I, Berk M, Dean OM, Taylor B, Broadley S, Lechner-Scott J, Jacka FN, Lucas RM, Ponsonby AL; RELIEF Trial team..
The effect of emerging nutraceutical interventions for clinical and biological outcomes in multiple sclerosis: A systematic review.
Mult Scler Relat Disord. 2019 Nov 2;37:101486. doi: 10.1016/j.msard.2019.101486. [Epub ahead of print] Review.
Summary(link is external)
Pathophysiology
Neumann B, Segel M, Chalut KJ, Franklin RJ.
Remyelination and ageing: Reversing the ravages of time.
Mult Scler. 2019 Dec;25(14):1835-1841. doi: 10.1177/1352458519884006. Epub 2019 Nov 5.
Summary(link is external)
Read the full text of this paper (link is external)
Prognosis
Marck CH, Aitken Z, Simpson S, Weiland TJ, Jelinek GA.
Does a modifiable risk factor score predict disability worsening in people with multiple sclerosis?
Mult Scler J Exp Transl Clin. 2019 Oct 11;5(4):2055217319881769. doi: 10.1177/2055217319881769. eCollection 2019 Oct-Dec.
Summary(link is external)
Read the full text of this paper (link is external)
Provision of care
Latorraca CO, Martimbianco ALC, Pachito DV, Torloni MR, Pacheco RL, Pereira JG, Riera R.
Palliative care interventions for people with multiple sclerosis.
Cochrane Database Syst Rev. 2019 Oct 22;10:CD012936. doi: 10.1002/14651858.CD012936.pub2. [Epub ahead of print] Review.
Summary(link is external)
Psychological aspects
McKay KA, Ernstsson O, Manouchehrinia A, Olsson T, Hillert J.
Determinants of quality of life in pediatric- and adult-onset multiple sclerosis.
Neurology. 2019 Nov 15. pii: 10.1212/WNL.0000000000008667. doi: 10.1212/WNL.0000000000008667. [Epub ahead of print]
Summary(link is external)
Biernacki T, Sandi D, Kincses ZT, Füvesi J, Rózsa C, Mátyás K, Vécsei L, Bencsik K.
Contributing factors to health-related quality of life in multiple sclerosis.
Brain Behav. 2019 Dec;9(12):e01466. doi: 10.1002/brb3.1466. Epub 2019 Nov 11.
Summary(link is external)
Read the full text of this paper (link is external)
Yael G, Nancy C, John D.
Money management in multiple sclerosis: the role of cognitive, motor, and affective factors.
Front Neurol. 2019 Oct 23;10:1128. doi: 10.3389/fneur.2019.01128. eCollection 2019.
Summary(link is external)
Read the full text of this paper (link is external)
Cook JE.
Guest editorial: stigma and identity in multiple sclerosis.
Int J MS Care. 2019 Sep-Oct;21(5):iv. doi: 10.7224/1537-2073.2019-090. No abstract available.
Summary(link is external)
Read the full text of this paper (link is external)
Barker AB, Smale K, Hunt N, Lincoln NB, das Nair R.
Experience of identity change in people who reported a diagnosis of multiple sclerosis: a qualitative inquiry.
Int J MS Care. 2019 Sep-Oct;21(5):235-242. doi: 10.7224/1537-2073.2018-069.
Summary(link is external)
Read the full text of this paper (link is external)
Spencer LA, Silverman AM, Cook JE.
Adapting to multiple sclerosis stigma across the life span.
Int J MS Care. 2019 Sep-Oct;21(5):227-234. doi: 10.7224/1537-2073.2019-056.
Summary(link is external)
Read the full text of this paper (link is external)
Hategeka C, Traboulsee AL, McMullen K, Lynd LD.
Association of unemployment and informal care with stigma in multiple sclerosis: evidence from the survey on living with neurological conditions in Canada.
Int J MS Care. 2019 Sep-Oct;21(5):214-225. doi: 10.7224/1537-2073.2017-108.
Summary(link is external)
Read the full text of this paper (link is external)
Stevens SD, Thompson NR, Sullivan AB.
Prevalence and correlates of body image dissatisfaction in patients with multiple sclerosis.
Int J MS Care. 2019 Sep-Oct;21(5):207-213. doi: 10.7224/1537-2073.2018-066.
Summary(link is external)
Read the full text of this paper (link is external)
Grech LB, Kiropoulos LA, Kirby KM, Butler E, Paine M, Hester R.
Importance of coping in the relationship between executive function and quality of life in people with multiple sclerosis.
Int J MS Care. 2019 Sep-Oct;21(5):201-206. doi: 10.7224/1537-2073.2018-029.
Summary(link is external)
Read the full text of this paper (link is external)
Ballesteros J, Martínez-Ginés ML, García-Domínguez JM, Forero L, Prefasi D, Maurino J; W-IMPACT Study Group..
Assessing stigma in multiple sclerosis: psychometric properties of the eight-item stigma scale for chronic illness (SSCI-8).
Int J MS Care. 2019 Sep-Oct;21(5):195-199. doi: 10.7224/1537-2073.2018-053.
Summary(link is external)
Read the full text of this paper (link is external)
Leavitt VM, Riley CS, De Jager PL, Bloom S.
eSupport: Feasibility trial of telehealth support group participation to reduce loneliness in multiple sclerosis.
Mult Scler. 2019 Oct 31:1352458519884241. doi: 10.1177/1352458519884241. [Epub ahead of print]
Summary(link is external)
Rehabilitation
Richardson EV, Fifolt M, Barstow EA, Silveira SL, Sikes EM, Motl RW.
The priorities of neurologists for exercise promotion in comprehensive multiple sclerosis care.
Mult Scler Relat Disord. 2019 Oct 31;38:101482. doi: 10.1016/j.msard.2019.101482. [Epub ahead of print]
Summary(link is external)
Boesen F, Nørgaard M, Skjerbæk AG, Rasmussen PV, Petersen T, Løvendahl B, Trénel P.
Can inpatient multidisciplinary rehabilitation improve health-related quality of life in MS patients on the long term - The Danish MS Hospitals Rehabilitation Study.
Mult Scler. 2019 Nov 5:1352458519884244. doi: 10.1177/1352458519884244. [Epub ahead of print]
Summary(link is external)
Read the full text of this paper (link is external)
Coghe G, Corona F, Pilloni G, Porta M, Frau J, Lorefice L, Fenu G, Cocco E, Pau M.
Is there any relationship between upper and lower limb impairments in people with multiple sclerosis? A kinematic quantitative analysis.
Mult Scler Int. 2019 Oct 9;2019:9149201. doi: 10.1155/2019/9149201. eCollection 2019.
Summary(link is external)
Read the full text of this paper (link is external)
Torres-Pareja M, Sánchez-Lastra MA, Iglesias L, Suárez-Iglesias D, Mendoza N, Ayán C.
Exercise interventions for improving flexibility in people with multiple sclerosis: a systematic review and meta-analysis.
Medicina (Kaunas). 2019 Nov 2;55(11). pii: E726. doi: 10.3390/medicina55110726. Review.
Summary(link is external)
Read the full text of this paper (link is external)
Fasczewski KS, Cook HM, Campbell KE, Anderes B.
I ride for MS: The impact of bike MS participation on motivation for physical activity in individuals with multiple sclerosis.
Disabil Health J. 2019 Oct 26:100853. doi: 10.1016/j.dhjo.2019.100853. [Epub ahead of print]
Summary(link is external)
van der Feen FE, de Haan GA, van der Lijn I, Heersema DJ, Meilof JF, Heutink J.
Independent outdoor mobility of persons with multiple sclerosis - A systematic review.
Mult Scler Relat Disord. 2019 Oct 22;37:101463. doi: 10.1016/j.msard.2019.101463. [Epub ahead of print] Review.
Summary(link is external)
Read the full text of this paper (link is external)
Tablerion JM, Wood TA, Hsieh KL, Bishnoi A, Sun R, Hernandez M, An R, Sosnoff JJ.
Motor learning in people with multiple sclerosis: A systematic review and meta-analysis.
Arch Phys Med Rehabil. 2019 Oct 24. pii: S0003-9993(19)31312-7. doi: 10.1016/j.apmr.2019.09.014. [Epub ahead of print] Review.
Summary(link is external)
Sikes EM, Cederberg KL, Sandroff BM, Bartolucci A, Motl RW.
Quantitative synthesis of timed 25-foot walk performance in multiple sclerosis.
Arch Phys Med Rehabil. 2019 Oct 24. pii: S0003-9993(19)31313-9. doi: 10.1016/j.apmr.2019.08.488. [Epub ahead of print]
Summary(link is external)
Ryan JM, Fortune J, Stennett A, Kilbride C, Lavelle G, Hendrie W, DeSouza L, Abdul M, Brewin D, David L, Anokye N, Victor C, Norris M.
Safety, feasibility, acceptability and effects of a behaviour-change intervention to change physical activity behaviour among people with multiple sclerosis: Results from the iStep-MS randomised controlled trial.
Mult Scler. 2019 Oct 31:1352458519886231. doi: 10.1177/1352458519886231. [Epub ahead of print]
Summary(link is external)
Arntzen EC, Øberg GK, Gallagher S, Normann B.
Group-based, individualized exercises can provide perceived bodily changes and strengthen aspects of self in individuals with MS: a qualitative interview study.
Physiother Theory Pract. 2019 Oct 26:1-16. doi: 10.1080/09593985.2019.1683923. [Epub ahead of print]
Summary(link is external)
Read the full text of this paper (link is external)
Self-management
Winberg C, Kylberg M, Pettersson C, Harnett T, Hedvall PO, Mattsson T, Månsson Lexell E.
Feeling controlled or being in control? Apps for self-management among older people with neurological disability.
Disabil Rehabil Assist Technol. 2019 Nov 11:1-6. doi: 10.1080/17483107.2019.1685017. [Epub ahead of print]
Summary(link is external)
Read the full text of this paper (link is external)
Stem cells
De Kleermaeker FGCM, Uitdehaag BMJ, van Oosten BW.
Patients' expectations of autologous hematopoietic stem cell transplantation as a treatment for MS.
Mult Scler Relat Disord. 2019 Oct 24;37:101467. doi: 10.1016/j.msard.2019.101467. [Epub ahead of print]
Summary(link is external)
Symptoms and symptom management
Brandstadter R, Fabian M, Leavitt VM, Krieger S, Yeshokumar A, Katz Sand I, Klineova S, Riley CS, Lewis C, Pelle G, Lublin FD, Miller AE, Sumowski JF.
Word-finding difficulty is a prevalent disease-related deficit in early multiple sclerosis.
Mult Scler. 2019 Nov 19:1352458519881760. doi: 10.1177/1352458519881760. [Epub ahead of print]
Summary(link is external)
Kratz AL, Atalla M, Whibley D, Myles A, Thurston T, Fritz NE.
Calling out MS fatigue: feasibility and preliminary effects of a pilot randomized telephone-delivered exercise intervention for multiple sclerosis fatigue.
J Neurol Phys Ther. 2020 Jan;44(1):23-31. doi: 10.1097/NPT.0000000000000296.
Summary(link is external)
Read the full text of this paper (link is external)
Patten SB.
Psychopharmacology of multiple sclerosis.
Handb Clin Neurol. 2019;165:309-315. doi: 10.1016/B978-0-444-64012-3.00018-6.
Summary(link is external)
Sahin E, Hamamcı M, Kantekin Y.
Measurement of mucociliary clearance in the patients with multiple sclerosis.
Eur Arch Otorhinolaryngol. 2019 Nov 9. doi: 10.1007/s00405-019-05717-w. [Epub ahead of print]
Summary(link is external)
Huang MH, Fry D, Doyle L, Burnham A, Houston N, Shea K, Smith H, Wiske L, Goode J, Khitrik E, Kolanda M.
Effects of inspiratory muscle training in advanced multiple sclerosis.
Mult Scler Relat Disord. 2019 Nov 1;37:101492. doi: 10.1016/j.msard.2019.101492. [Epub ahead of print]
Summary(link is external)
Newland P, Oliver B, Newland JM, Thomas FP.
Testing feasibility of a mobile application to monitor fatigue in people with multiple sclerosis.
J Neurosci Nurs. 2019 Dec;51(6):331-334. doi: 10.1097/JNN.0000000000000479.
Summary(link is external)
Ferraro D, Annovazzi P, Moccia M, Lanzillo R, De Luca G, Nociti V, Fantozzi R, Paolicelli D, Ragonese P, Gajofatto A, Boffa L, Cavalla P, Lo Fermo S, Buscarinu MC, Lorefice L, Cordioli C, Calabrese M, Gallo A, Pinardi F, Tortorella C, Di Filippo M, Camera V, et al.
Characteristics and treatment of multiple sclerosis-related trigeminal neuralgia: An Italian multi-centre study.
Mult Scler Relat Disord. 2019 Oct 19;37:101461. doi: 10.1016/j.msard.2019.101461. [Epub ahead of print]
Summary(link is external)
Cederberg KLJ, Jeng B, Sasaki JE, Braley TJ, Walters AS, Motl RW.
Physical activity, sedentary behavior, and restless legs syndrome in persons with multiple sclerosis.
J Neurol Sci. 2019 Dec 15;407:116531. doi: 10.1016/j.jns.2019.116531. Epub 2019 Oct 12.
Summary(link is external)
Amato MP, Prestipino E, Bellinvia A, Niccolai C, Razzolini L, Pastò L, Fratangelo R, Tudisco L, Fonderico M, Mattiolo PL, Goretti B, Zimatore GB, Losignore NA, Portaccio E, Lolli F.
Cognitive impairment in multiple sclerosis: An exploratory analysis of environmental and lifestyle risk factors.
PLoS One. 2019 Oct 21;14(10):e0222929. doi: 10.1371/journal.pone.0222929. eCollection 2019. Erratum in: PLoS One. 2019 Nov 14;14(11):e0225494.
Summary(link is external)
Read the full text of this paper (link is external)
Vitamin D
Doosti-Irani A, Tamtaji OR, Mansournia MA, Ghayour-Mobarhan M, Ferns G, Daneshvar Kakhaki R, Rezaei Shahmirzadi A, Asemi Z.
The effects of vitamin D supplementation on expanded disability status scale in people with multiple sclerosis: A critical, systematic review and metaanalysis of randomized controlled trials.
Clin Neurol Neurosurg. 2019 Dec;187:105564. doi: 10.1016/j.clineuro.2019.105564. Epub 2019 Oct 14. Review.
Summary(link is external)
Work
Chalmer TA, Buron M, Illes Z, Papp V, Theodorsdottir A, Schäfer J, Hansen V, Asgari N, Skejø PB, Jensen HB, Sørensen PS, Magyari M.
Clinically stable disease is associated with a lower risk of both income loss and disability pension for patients with multiple sclerosis.
J Neurol Neurosurg Psychiatry. 2020 Jan;91(1):67-74. doi: 10.1136/jnnp-2019-321523. Epub 2019 Nov 14.
Summary(link is external)


Ozanimod (Zeposia) approved for relapsing remitting MS in Scotland
8 Feb 2021 - 00:00
The MS Trust is delighted that ozanimod (Zeposia) has been approved in Scotland for people with active relapsing remitting multiple sclerosis.


Exercise is good for your brain
3 Feb 2021 - 00:00
There is more to exercise than physical fitness. This review looks at recent research which shows how exercise has a direct beneficial effect on brain repair processes.


Covid-19 vaccines and MS: Part two
29 Jan 2021 - 00:00
Following our last interview on the subject of the Covid-19 vaccine and people with MS, we received a lot of follow up questions. To answer some of these, we spoke once again to Professor Alasdair Coles, Consultant Neurologist at Addenbrooke’s hospital.

Sign up to our emails
Get the latest news and research sent straight to your inbox. Find out first about the latest developments in MS treatments, plus updates on the work of the MS Trust.